Osiris Therapeutics researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its product Grafix is a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns. In addition, the Company offers BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery, and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects.

Type
Public
HQ
Columbia, US
Founded
1992
Size (employees)
211 (est)
Website
osiris.com
Osiris Therapeutics was founded in 1992 and is headquartered in Columbia, US
Report incorrect company information

Key People/Management at Osiris Therapeutics

Linda Chang

Linda Chang

Chief Financial Officer
Jason Keefer

Jason Keefer

Interim President & CEO, VP of Marketing

Osiris Therapeutics Office Locations

Osiris Therapeutics has an office in Columbia
Columbia, US (HQ)
7015 Albert Einstein Drive
Show all (1)
Report incorrect company information

Osiris Therapeutics Financials and Metrics

Osiris Therapeutics Financials

USD

Revenue (Q1, 2018)

31.6 m

Gross profit (Q1, 2018)

22.8 m

Gross profit margin (Q1, 2018), %

72%

Net income (Q1, 2018)

(2.3 m)

EBIT (Q1, 2018)

(2.5 m)

Market capitalization (31-Oct-2017)

172.3 m

Closing share price (31-Oct-2017)

4.7

Cash (31-Mar-2018)

3.4 m
Osiris Therapeutics's current market capitalization is $172.3 m.
Annual
USDFY, 2013FY, 2014

EBIT

(2.8 m)1.7 m

Net Income

41.6 m(1.8 m)
Quarterly
USDQ1, 2018

Revenue

31.6 m

Cost of goods sold

8.9 m

Gross profit

22.8 m

Gross profit Margin, %

72%
Annual
USDFY, 2013FY, 2014FY, 2017

Cash

2.4 m2.2 m3.1 m

Accounts Receivable

15.3 m10 m26.1 m

Inventories

355 k650 k11.3 m

Current Assets

84.1 m95.9 m72.9 m
Quarterly
USDQ1, 2018

Cash

3.4 m

Accounts Receivable

26.5 m

Inventories

11 m

Current Assets

73.3 m
Annual
USDFY, 2013FY, 2014FY, 2017

Net Income

8.8 m

Depreciation and Amortization

587 k940 k688 k

Inventories

(651 k)(9 m)

Accounts Payable

(2.8 m)(57 k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2018

Net Income

(2.3 m)

Depreciation and Amortization

211 k

Inventories

1.7 m2.3 m5.5 m8.8 m11.9 m13.3 m15.8 m

Accounts Payable

4 m8 m9.3 m9.8 m9.2 m9.6 m
USDY, 2018

Financial Leverage

2 x
Show all financial metrics
Report incorrect company information

Osiris Therapeutics News and Updates

Report incorrect company information